The latest price target for Fate Therapeutics (NASDAQ:FATE) was reported by HC Wainwright & Co. on August 22, 2024. The analyst firm set a price target for $5.00 expecting FATE to rise to within 12 months (a possible 47.49% upside). 23 analyst firms have reported ratings in the last year.

The latest analyst rating for Fate Therapeutics (NASDAQ:FATE) was provided by HC Wainwright & Co., and Fate Therapeutics reiterated their neutral rating.

The last upgrade for Fate Therapeutics Inc happened on June 17, 2024 when Piper Sandler raised their price target to $6. Piper Sandler previously had a neutral for Fate Therapeutics Inc.

The last downgrade for Fate Therapeutics Inc happened on January 24, 2023 when HC Wainwright & Co. changed their price target from $115 to $7 for Fate Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fate Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fate Therapeutics was filed on August 22, 2024 so you should expect the next rating to be made available sometime around August 22, 2025.

While ratings are subjective and will change, the latest Fate Therapeutics (FATE) rating was a reiterated with a price target of $5.00 to $5.00. The current price Fate Therapeutics (FATE) is trading at is $3.39, which is out of the analyst’s predicted range.